-
10% off sale equity! Why did he give up the listed company he built first hand?
Time of Update: 2017-05-12
More than 20 years of entrepreneurship, entering the capital market, exceeding the annual growth rate of the industry, why do you sell all your shares at a discount? On May 10, Xinbang pharmaceutical
-
FDA approved the second PD-L1 inhibitor this year, and domestic innovative drugs did not lose
Time of Update: 2017-05-12
Recently, the FDA approved the drug durvalumab (trade name: imfinzi) of AstraZeneca for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who developed disease pr
-
General manager of multinational pharmaceutical company in China! Who's next?
Time of Update: 2017-05-09
Ten years ago, there were only a few mainland Chinese who could be the general manager of foreign enterprises in China, such as Wu Xiaobin and Deng Jianmin Now they have a grand view! Two days ago, Wa
-
Five magic weapons for generic companies to win! Hengrui, LVYE, xinlitai and other five enterprises play like this
Time of Update: 2017-05-09
On May 2, Guangdong Drug Trade Center released the list of goods not supplied according to the contract and not supplied in time on its official website, requiring the manufacturers to supply and dist
-
Three winning rules for innovative drug investment! Attached with a panoramic view of Chinese pharmaceutical enterprises' innovation background
Time of Update: 2017-05-08
Innovative drug investment is full of challenges for every investor This is a multiple game of science, commercial and finance To understand the disease and technology, to predict the future market pe
-
Shiyao overtakes again, and becomes the "second imitation" manufacturer of dashatini tablets?
Time of Update: 2017-05-07
The recent drug registration of Petrochemicals Group in China is really eye-catching For example: ① when petrochemicals and Hengrui are out of the game, the time left for metformin may not be much lon
-
Children's medicine market is just a superficial view? The latest battle report of 8 major pharmaceutical companies reveals the truth
Time of Update: 2017-05-06
Wonderful content the second child era has given new opportunities to children's medicine market Both policy support and market orientation are promoting the development of children's medicine At pres
-
Domestic pharmaceutical companies want to be first in class. How to choose the three business models?
Time of Update: 2017-05-05
Authorized introduction, independent R & D and active capital investment are three business models in the field of "true innovation" The desire for first in class is growing in China Absolute innovati
-
Commercial bribery has become a "stumbling block" for pharmaceutical enterprises. Has shenghuaxi pharmaceutical industry been launched
Time of Update: 2017-05-04
Securities Daily reported on May 2 that the issuance and review meeting held on that day reviewed the IPO applications of 7 companies, among which 6 companies including Zheshang Securities Co., Ltd we
-
Hengrui, Renfu, Huahai and other 19 pharmaceutical companies set up venture capital funds! They want to circle the land?
Time of Update: 2017-05-04
In 2016, 39 venture capital funds related to the pharmaceutical and health industry were established! In the past year, there have been 19 industrial funds initiated by pharmaceutical enterprises, amo
-
Why is the legend of the highest position local professional manager in a multinational company?
Time of Update: 2017-04-30
none="shifuMouseDownCard('shifu_c_029')" label="Copyright Reserved by PLAYHUDONG." style="margin: 1em 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Mic
-
How does the market of hepatitis C drugs change when BMS double weight products are launched?
Time of Update: 2017-04-28
On April 28, CFDA official website announced the approval of the combination therapy of BMS dalatavir hydrochloride and ashurevir soft capsule for hepatitis C, and another strong march into the fierce
-
The first deuterium drug was approved or led to a wave, and domestic and foreign deuterium drug research and development enterprises briefly cited one or two
Time of Update: 2017-04-27
On April 3, 2017, the FDA officially approved Teva's Huntington's chorea drug, austedo, which is a small molecule oral inhibitor targeting VMAT-2 It is also the first deuterium drug approved by the FD
-
Kyushu has made great progress against the trend, with revenue exceeding 60 billion! Why?
Time of Update: 2017-04-26
In the eyes of the outside world, 2016 is the year when the two major policies of "replacing business tax with value-added tax" and "two vote system" affect the life and death of pharmaceutical busine
-
Two kinds of oral hypoglycemic compound preparations have entered the country one after another! There are many new drug approval highlights in the near future
Time of Update: 2017-04-26
Last week, four new class 1 drugs were approved for clinical use: sh229 tablets, InBev sodium tablets, shenggliptin phosphate tablets and zsp1602 capsules AstraZeneca's salgretine metformin sustained-
-
Why can a new deal from CFDA let him leave the company?
Time of Update: 2017-04-22
The new drug application process of international multi clinical centers will be simplified, which will bring significant business opportunities for innovative drugs to enter the Chinese market Under
-
Regulation makes drug registration more efficient
Time of Update: 2017-04-22
The backlog of drug registration applications in China has gone through several times, which is one of the main problems in drug registration evaluation in China In this regard, Chen Guiliang, directo
-
Yunnan Hong founder 84 years old to start a business again to obtain financing, inventory pharmaceutical industry "Chu Shijian" people!
Time of Update: 2017-04-20
They used to be the most famous reform adventurers in the pharmaceutical industry They reached the top of their lives because they created a company, but some of them had no choice but to sell the com
-
Compound antihypertensive drugs rush into the 10 billion market: Top 5 varieties account for nearly 90%
Time of Update: 2017-04-20
According to the data of 2015 China's guidelines for rational use of drugs in the treatment of hypertension, the number of Chinese adults with hypertension has reached 298 million At present, the awar
-
Pharmaceutical giants do not love R & D and marketing
Time of Update: 2017-04-19
12 enterprises, such as Shanghai Pharmaceutical (19.88, - 0.17, - 0.85%) (02607 HK), Fosun Pharmaceutical (28.6, 0.30, 1.06%) (02196 HK), Hengrui pharmaceutical, dong'a Ejiao, etc., made net profit an
